🇺🇸 GH — Guardant Health, Inc.

Salud Compra fuerte
← Volver

Precio actual

175,00 USD

Máx. histórico

187,22

29 días

Caída desde máximo

-6,53%

Rango 52 semanas

74,55 – 191,05

Variación hoy

+2,50%

Cierre anterior

170,73

Rango de hoy

167,31 – 178,38

Volumen hoy

1.720.775

Peor caída histórica

-91,03%

12/02/2021 → 19/04/2024

Recuperado en 881 días

Volatilidad anualizada ⓘ

67,35%

Información
Nombre completo
Guardant Health, Inc.
Divisa
USD
Mercado
NasdaqGS
Sector
Salud
Industria
Diagnostics & Research
Empleados
2.490
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
202,24 USD (puede no estar actualizado)
Primera cotización
04/10/2018
Precio actualizado
hace 14 horas
Sobre la empresa

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutation profiling; Guardant360 Liquid test, which measures 740+ genes and supports all guideline-recommended biomarkers; Guardant Reveal test, a blood test that utilizes circulating tumor DNA to detect cancer at the molecular level; and Guardant360 Tissue test, a molecular profiling test for tumor tissue that provides genomic, transcriptomic, and epigenomic insights. It also provides Shield blood test for colorectal cancer screening in adults. In addition, the company offers GuardantINFINITY test that provides insights into the complexities of tumor molecular profiles and immune response to advance cancer research and therapy development; GuardantOMNI test covers 500 genes, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications; GuardantINFORM, which provides longitudinal biological insight into tumor evolution alongside longitudinal clinical outcomes; and GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies. Further, it provides Smart Platform, which delivers multiomic insights leveraging genomic, epigenomic, and RNA-based data that are scalable from research to the clinic. Additionally, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kit fulfillment and delivery of Shield screening tests. It has a strategic collaboration with Nuvalent, Inc. for oncology drug development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
04/03/2025 39,85 42,58 39,17 41,48 +1,82% 8,56% 2.946.300
03/03/2025 42,71 43,88 40,47 40,74 -4,25% 7,98% 1.863.000
28/02/2025 41,72 42,67 41,11 42,55 +1,04% 3,74% 1.488.600
27/02/2025 43,19 43,23 41,48 42,11 -2,50% 4,05% 1.642.400
26/02/2025 41,41 43,83 41,39 43,19 +7,04% 5,89% 2.665.600
25/02/2025 42,46 44,01 40,28 40,35 -4,92% 8,78% 2.396.800
24/02/2025 43,24 45,98 42,25 42,44 -1,00% 8,63% 2.571.100
21/02/2025 48,50 49,00 42,19 42,87 -9,56% 14,04% 5.736.000
20/02/2025 48,33 49,35 46,83 47,40 -3,27% 5,21% 3.028.800
19/02/2025 48,47 49,50 47,56 49,00 +1,51% 4,00% 2.404.100
18/02/2025 49,90 49,90 47,03 48,27 +0,31% 5,75% 2.206.400
14/02/2025 47,50 49,48 47,27 48,12 +2,43% 4,65% 2.129.900
13/02/2025 45,73 47,55 45,71 46,98 +3,53% 4,02% 2.414.000
12/02/2025 42,50 45,75 42,21 45,38 +4,08% 8,33% 1.397.600
11/02/2025 43,71 44,40 42,76 43,60 -1,80% 3,75% 1.545.800
10/02/2025 44,59 44,61 41,79 44,40 -0,16% 6,32% 2.728.200
07/02/2025 44,52 45,97 44,26 44,47 -3,51% 3,84% 6.162.900
06/02/2025 47,72 48,08 46,02 46,09 -3,17% 4,32% 1.283.000
05/02/2025 47,36 48,58 47,07 47,60 +0,91% 3,19% 1.073.300
04/02/2025 48,45 48,45 46,84 47,17 -0,84% 3,32% 1.332.100
03/02/2025 44,51 47,63 44,10 47,57 +1,26% 7,93% 1.826.500
31/01/2025 49,77 49,77 46,73 46,98 -5,93% 6,11% 2.398.500
30/01/2025 48,97 50,89 48,32 49,94 +4,81% 5,25% 3.241.600
29/01/2025 48,30 48,94 47,50 47,65 -1,26% 2,98% 1.484.400
28/01/2025 47,53 48,29 46,71 48,26 +2,72% 3,32% 2.240.700
27/01/2025 46,94 47,78 45,59 46,98 -0,49% 4,67% 1.842.000
24/01/2025 48,26 48,60 46,43 47,21 -2,86% 4,50% 1.711.400
23/01/2025 46,80 48,82 45,42 48,60 +2,97% 7,26% 2.764.700
22/01/2025 45,13 49,86 44,77 47,20 +4,59% 11,28% 5.915.600
21/01/2025 39,04 45,68 38,32 45,13 +23,10% 18,85% 7.159.400